DRUG Bright Minds Biosciences Inc.
-
Bright Minds Biosciences Beat Consensus Estimates
Friday, August 14, 2026 · 12:00 AM ET
Bright Minds Biosciences (DRUG) reported a loss of $0.17 per share on revenue of $0.00 million for the fiscal third quarter ended June 2026. The consensus estimate was a loss of $1.39 per share. The company beat consensus estimates by 87.77%.
Bright Minds Biosciences is a biotechnology company. It focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain. Bright Minds Biosciences is based in VANCOUVER, British Columbia.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.17)
Earnings Whisper®
—
Consensus Estimate
($1.39)
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—